Manufacturing: Page 2
-
Permission granted by West Pharmaceutical Services
Sponsored by West Pharmaceutical ServicesEarly decisions to de-risk the transition to combination products
Speeding up the drug development process through a less optimized containment and delivery system may have been an option in the past, but both expectations and the competitive environment are changing.
March 20, 2023 -
Novartis
Sandoz, betting on biosimilar sales, to build new production plant
The Novartis division will invest at least $400 million in a new manufacturing facility in Slovenia amid expectations that demand for copycat biologics will surge in the coming years.
By Delilah Alvarado • March 9, 2023 -
Novartis
Novartis takes step toward expanding supply of in-demand cancer drug
The company has struggled to maintain supply of its prostate cancer drug Pluvicto, hampered by production issues and higher-than-expected demand.
By Delilah Alvarado • March 3, 2023 -
Permission granted by Vector BioMed
A startup launches with plans to open up a gene and cell therapy bottleneck
The pipeline of CAR-T therapies and ex vivo gene therapies has swelled in recent years, but manufacturing hasn’t been able to keep up with demand.
By Gwendolyn Wu • Jan. 31, 2023 -
Lilly to boost diabetes drug production with $450M factory investment
The pharma aims to double its manufacturing capacity for drugs like Mounjaro and Trulicity as competition with rival Novo Nordisk heats up.
By Jonathan Gardner • Jan. 24, 2023 -
Permission granted by Stevanato Group
Sponsored by Stevanato GroupThe inspection challenges posed by the self-administration trend
Automatic visual inspection: rising to the challenges of syringe inspection.
Dec. 19, 2022 -
Novo Nordisk
Novo Nordisk to boost drug manufacturing in Denmark
The Danish drugmaker has invested heavily in expanding its production capacity for oral and injectable drugs. A new $744 million project is the latest investment.
By Christopher Newman • Nov. 22, 2022 -
Permission granted by MMIT
Sponsored by MMITIntegrating lab data into your physician engagement strategy: 5 key benefits
Normalized lab data can help pharma companies promote their therapies to a targeted audience.
By Ritupriya Yamujala • Nov. 14, 2022 -
Copyright © 2022 Miltenyi Biotec B.V. & Co. KG. All rights reserved.
Sponsored by Miltenyi BiotecModular plug-and-produce facilities for cell therapies
Commercial-scale production is pivotal for the success of cell therapy. Is modularity the solution?
Nov. 7, 2022 -
Amicus Therapeutics
FDA again delays review of Amicus rare disease drug
For the second time this year, the agency has put off a decision on Amicus' therapy for Pompe disease. European regulators are also reviewing the treatment and could soon issue an opinion.
By Christopher Newman • Oct. 31, 2022 -
Mateusz/Shutterstock.com
Sponsored by Emergent BiosolutionsThe demand for nanoparticles in drug formulation is rising
Collaborating with an experienced partner, such as a Contract Development & Manufacturing Organization (CDMO), could prove to be invaluable in developing nano-based systems.
By Kate Silver • Oct. 17, 2022 -
Permission granted by Aldevron
Sponsored by AldevronExpediting IND applications with drug master files
By taking advantage of pre-filed DMFs, researchers benefit from the value, time savings and reduced complexities of having someone else do the heavy lifting for key components of the final drug product.
Oct. 10, 2022 -
Jacob Bell / BioPharma Dive
Merck expands Singapore hub to support Keytruda, Gardasil
The company opened a packaging facility for its two top-selling products and began work on a plant that will produce next-generation inhalers.
By Christopher Newman • Oct. 6, 2022 -
Thomas Lohnes via Getty Images
BioNTech to build an mRNA hub in Australia
A new agreement with the Australian government will bring messenger RNA research and manufacturing capabilities to the country, adding to the COVID-19 vaccine developer’s global expansion efforts.
By Delilah Alvarado • Oct. 6, 2022 -
Stock via Getty Images
Takeda to stop making parathyroid drug Natpara in 2024 after production challenges
The Japanese drugmaker said it was unable to resolve manufacturing problems that led to a 2019 recall of the drug, which treats hypoparathyroidism.
By Christopher Newman • Oct. 4, 2022 -
Permission granted by Aldevron
Sponsored by AldevronStandardized materials: Meeting the demand for gene therapies
With supply and labor constraints creating backlogged custom-manufacturing schedules, developers have felt the pain in cost and speed to market.
Sept. 26, 2022 -
Novartis
Novartis funnels $300M into early biologic drug manufacturing
The investment is meant to improve Novartis’ capacity for developing and manufacturing biologic medicines that make up a larger share of its pipeline.
By Christopher Newman • Sept. 12, 2022 -
Getty Images
FDA holds back Alvotech’s Humira biosimilar over manufacturing issues
The company received a complete response letter, but still expects to win approval of the copycat drug in time to launch it in the U.S. next year.
By Jonathan Gardner • Sept. 6, 2022 -
Courtesy of Sonoma Biotherapeutics
‘Treg’ startup Sonoma expands with plans for manufacturing plant
The biotech, launched by immunologist Jeffrey Bluestone, is developing regulatory T cell therapies for autoimmune and inflammatory diseases.
By Ned Pagliarulo • Aug. 24, 2022 -
Mario Tama via Getty Images
US speeds rollout of monkeypox vaccine, treatment
The Biden administration next week will provide 1.8 million doses of the Jynneos vaccine and 50,000 courses of antiviral Tpoxx to states and local governments.
By Christopher Newman • Aug. 19, 2022 -
Courtesy of Bristol Myers Squibb and Bluebird bio
Bristol Myers CAR-T sales rise despite production problems
Demand has increased faster than Bristol Myers can make Abecma, although the company said supply is improving. A manufacturing issue for Breyanzi, meanwhile, impacted sales.
By Ned Pagliarulo • July 27, 2022 -
Justin Sullivan via Getty Images
California to manufacture its own insulin, governor says
Gov. Gavin Newsom announced a $100 million budget to create a production facility and to develop affordable insulin products, saying the medicines’ high cost “epitomizes market failures.”
By Susan Kelly • July 11, 2022 -
Stock via Getty Images
Resilience, a well-funded manufacturing startup, joins with the Parker Institute to make cancer drugs
The unusual biotech, which just raised $625 million earlier this week, will work with the immunotherapy center under a five-year agreement to create and spin off new companies.
By Kristin Jensen • June 9, 2022 -
Getty / Edited by BioPharma Dive
Astellas, despite recent setbacks, opens $100M gene therapy plant
The opening of the plant, which could create more than 200 new jobs, comes on the heels of several significant issues with the company’s most advanced gene therapy program.
By Jacob Bell • June 8, 2022 -
Spencer Platt via Getty Images
Pfizer to invest $120M, add jobs in Paxlovid production push
After initially struggling to meet demand for Paxlovid, Pfizer is putting significant resources toward expanding an important manufacturing plant in Michigan.
By Delilah Alvarado • June 7, 2022
Previous
